Reported by Asian hospital & Heaithcare Management / Sep 26, 2023
HoneyNaps has announced the FDA approval for its SOMNUM AI sleep disease analysis algorithm is a significant milestone in the field of sleep disorder diagnosis and management.
HoneyNaps' SOMNUM AI solution is revolutionising the diagnosis of sleep disorders by combining deep learning-based AI with eXplainable Medical AI (XAI) technology. This innovation streamlines the analysis of complex sleep biosignals, making it more efficient, accurate, and accessible, ultimately improving the quality of care for individuals with sleep-related health issues.
During polysomnography, a comprehensive sleep study, a variety of sleep biosignals are continuously monitored to assess sleep status and diagnose sleep disorders. These biosignals include electroencephalograms (EEG) to track brain activity, electrooculograms (EOG) for eye movement monitoring, chin and leg electromyograms (EMG) to measure muscle activity, electrocardiograms (ECG) for heart activity assessment, respiratory airflow and effort monitoring, oxygen saturation measurement, posture tracking, and snoring detection.
To address the challenges associated with the time-consuming and labour-intensive process of interpreting sleep biosignals, extensive research efforts have been dedicated to developing AI-based reading systems.
While skilled personnel may spend three to four hours analysing these results manually, AI reading systems have emerged as a valuable tool to enhance efficiency and accuracy in the assessment of sleep health, making sleep disorder diagnosis more accessible and timely.